Barclays Chief Loses Credibility Over Bonuses Are Demographics Really Destiny? GSK - The Quiet Turnaround Post your comment!
dividends at an impressive rate. Companies in the healthcare sector are some of the safest dividend investments. GlaxoSmithKline ( GSK ) is one of these companies - It operates in three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The stock
drug, Epanova , infringes on one of Vascepa's patents. Epanova's target user population is the same as Vascepa's and GSK 's Lovaza . AZN expects the FDA to rule on Epanova's NDA by May 5. Lovaza sales are ~$1B. Post your comment!
Executive Summary Over the past few years, GSK has been quietly executing on an impressive ..... that management is committed to increase, GSK is a stock that should provide a solid return ..... past 5 year bull market, GlaxoSmithKline ( GSK ) stock has underperformed the S&P 500
Electronics SSNLF 19 Blend N/A Cnsumer Elct. N/A Schneider Electric SBGSY 19 Blend 58 Industrials N/A GlaxoSmithKline GSK 18 Blend/Value 8 Drug Mfr. UBS UBS 17 Blend 29 Banks-Global Akzo Nobel AKZOY 16 Blend 164 Chemicals N/A BG Group BRGYY
Part of Theravance ( THRX ) will separate from partner GlaxoSmithKline ( GSK ) next quarter. Theravance Biopharma, the new firm, will retain the rights to Relvar, Breo and Anoro Ellipta drugs, with combined
GlaxoSmithKline ( GSK -0.7% ) submits its supplemental new drug application ((sNDA)) for its drug Promacta for the treatment of cytopenias
GSK ( GSK ) has called it quits on its GSK2586184 treatment for lupus - which it's developing with Belgian biotech Galapagos ( OTC:GLPGF ) - after a Phase 2 study failed to demonstrate a positive effect. A Phase1/2 trial for ulcerative colitis
Earlier this month, the FDA granted Breakthrough Therapy designation for Promacta in patients with severe aplastic anaemia. Press release LGND +3.6% , GSK flat Post your comment!
By Life Sciences Report : Biotech investing is a risky business, so investors should thoroughly examine a company's vital statistics before taking the plunge. That's the recommendation of Managing Director Debjit Chattopadhyay of Emerging Growth Equities, who brings a strict scientific discipline